Puneet Varma (Editor)

ISTA Pharmaceuticals

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Subsidiary

Website
  
www.istavision.com

Industry
  
Pharmaceuticals

Founded
  
1992

ISTA Pharmaceuticals mediamarketwirecomattachments20110231297ISTA

Key people
  
Vicente Anido Jr., Ph.D., President, Chief Executive Officer, Glenn E. Davis, Vice President, Chief Compliance Officer, Marvin J. Garrett, Vice President, Regulatory Affairs, Quality & Compliance, Kathleen McGinley, Vice President, Human Resources & Corporate Services, Kirk McMullin, Vice President, Operations Timothy R. McNamara, PharmD, Vice President, Clinical Research & Medical Affairs Tom Mitro, Vice President, Sales & Marketing

Products
  
Bromday, Bepreve, Xibrom, Istalol, Vitrase

Headquarters
  
Irvine, California, United States

Ista pharmaceuticals ceo dr vicente anido


ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specializes in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. ISTA was acquired by Bausch & Lomb on March 26, 2012.

Contents

In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.

Products

  • Bromday (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction
  • Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of itching associated with signs and symptoms of allergic conjunctivitis
  • Xibrom (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery (no longer being manufactured as of February 2011)
  • Istalol (timolol maleate ophthalmic solution) 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
  • Vitrase (hyaluronidase injection) Ovine, 200 USP Units/mL for use as an adjuvant to increase the absorption and ispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents

    • Litigation

    On May 24, 2013, ISTA Pharmaceuticals entered a guilty plea to federal felony charge of conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. ISTA agreed to pay $33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.

    References

    ISTA Pharmaceuticals Wikipedia
    (Text) CC BY-SA